1. NICE: Attention deficit hyperactivity disorder: diagnosis and management. National Clinical Practice Guideline Number 72 (2008; includes 2016 updates).
https://www.nice.org.uk/guidance/cg72
(2016). Accessed 4 July 2016
2. Wolraich, M.L., Wibbelsman, C.J., Brown, T.E., Evans, S.W., Gotlieb, E.M., Knight, J.R., Ross, E.C., Shubiner, H.H., Wender, E.H., Wilens, T.: Attention-deficit/hyperactivity disorder among adolescents: a review of the diagnosis, treatment, and clinical implications. Pediatrics 115, 1734–1746 (2005)
3. Pliszka, S.R.: Psychiatric comorbidities in children with attention deficit hyperactivity disorder: implications for management. Paediatr. Drugs 5, 741–750 (2003)
4. Döpfner, M., Lehmkuhl, G., Schepker, R., Frölich, J.: Deutsche Gesellschaft für Kinder und Jugendpsychiatrie und Psychotherapie (2007) Hyperkinetische Störungen (F90).
http://www.awmf.org/leitlinien/detail/ll/028-019.html
(2007) Accessed 17 May 2016
5. Wu, E.Q., Hodgkins, P., Ben-Hamadi, R., Setyawan, J., Xie, J., Sikirica, V., Du, E.X., Yan, S.Y., Erder, M.H.: Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: a systematic literature review. CNS Drugs 26, 581–600 (2012)